KRAS and pancreatic neoplasm: We expanded our LiCor quantification analysis to include melanoma (A375) and colorectal (HT29) cells with BRAFV600E (Supplementary Figure S3) and a pancreatic cancer cell line with KRAS mutation (Capan-1) (Supplementary Figure S4).